Cervical Dysplasia and Cancer
Cervical dysplasia is the term used to describe abnormal cells on the cervix (the head and neck of the uterus). On a Pap smear report, dysplasia is referred to as cervical intraepithelial neoplasia (CIN) or squamous intraepithelial lesion (SIL). Cervical dysplasia is usually first discovered by Pap smear, where cells are swabbed from in and around the cervical os (opening of the cervix). Dysplastic changes on Pap smear are rated as "low grade" or "high grade;" high grade lesions are considered precursors to cervical cancer, while the significance of low grade dysplasia has not been established.
Cervical dysplasia and cervical cancer are strongly associated with, and believed to be caused by, specific subtypes of the sexually transmitted virus called HPV (human papillomavirus). Other subtypes of HPV cause genital and anal warts (condyloma acuminata) in men and women. HIV positive women have a high rate of persistent HPV infections, and a higher rate than HIV negative women with the types of HPV that are associated with the development of high grade dysplasia and cervical cancer. In one recent study, persistent HPV infections were found in 24 percent of HIV positive women but in only 4 percent of HIV negative women. Twenty percent of the HIV positive women and 3 percent of the HIV negative women had persistent infection with HPV 16 or HPV 18 viral types, which are most strongly associated with cervical cancer.
Numerous studies have also documented that HIV positive women are more likely than HIV negative women to have cervical dysplasia. A large study comparing HIV positive and HIV negative women with documentation of dysplasia by colposcopy revealed 5 times as many HIV positive as HIV negative women with disease. Studies have observed, too, that the incidence of HPV-related dysplasia increases as immune function declines. Studies of HIVpositive women demonstrate that both rates of HPV infection and disease and of highgrade dysplasia increase as T cell counts decline.
The strong association between HPV infection and cervical dysplasia, the finding that HIV positive women are more likely to have persistent HPV infection of the specific subtypes associated with dysplasia, and that HIV positive women have a much higher incidence of dysplasia, all suggest that HIV-related immunosuppression either increases the risk of persistent HPV infection, or changes the natural history of HPV-related disease.
What, then, is the risk of developing invasive cervical cancer in women with HIV infection and HPV-related cervical dysplasia? The documentation of increased rates of cervical dysplasia prompted the CDC to add invasive cervical cancer to the AIDS surveillance case definition in 1993. However, much remains unknown about the incidence and natural history of this disease in HIV positive women.
Several small studies have found few, if any, cases of invasive cancer in HIV positive women with cervical dysplasia. In contrast, a study of women with invasive cervical cancer found that 19% of the cases in patients under the age of 50 were HIV positive. Other researchers have published case reports of rapidly progressive invasive cervical cancer in women with HIV. The bottom line is that the risk of invasive cervical cancer in HIV positive women with dysplasia may be increased, but the magnitude of the risk has not been adequately defined.
Early Detection and TreatmentAlthough many questions remain about the risk of cervical cancer in HIV positive women, it is important to remember that cervical cancer is largely a preventable disease. Screening by Pap smear for all sexually active women can identify those with dysplastic precursor lesions so that they can be treated and monitored before more serious disease develops. With the high rates of HPV infection and dysplasia known to exist in the HIV-infected population, screening, early diagnosis, treatment and careful monitoring are crucial. With no medical intervention available to prevent HPV infection and disease, regular Pap smears, lower genital tract inspection, and appropriate colposcopic follow-up and treatment of abnormalities are the best hope for preventing serious disease in women with cervical dysplasia. Colposcopy is performed to evaluate atypical and dysplastic smears.
Unfortunately, at this point there is not a consensus of opinion regarding frequency of Pap smears or the management of abnormal findings in HIV positive women. Many clinicians who care for large numbers of HIV positive women and experts in HIV primary care for women have recommended more aggressive surveillance for genital tract dysplasia than the published recommendations of the federal government's CDC or Agency for Health Care Policy and Research (AHCPR). These recommendations are based on the following facts:
This is a discouraging finding for women who must deal with the realities of diagnosis, evaluation, and treatment of dysplasia in the face of concurrent HIV disease. In theory it is possible that highly active antiretroviral therapies will improve local and systemic immune function and treatment success in affected women, but this remains to be seen. In the meantime, HIV-infected women with dysplasia are left to deal with the difficult reality of frequent evaluation and possible frequent repetitions of uncomfortable procedures and treatments in an effort to avoid cervical cancer.
This article was provided by AIDS Community Research Initiative of America. It is a part of the publication CRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.